Anzeige
Mehr »
Login
Donnerstag, 21.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Von Solarenergie zu digitalen Assets: Die Strategie hinter der 75-Prozent-Rallye
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESSWIRE
718 Leser
Artikel bewerten:
(2)

Walgreens Boots Alliance: Bridging the Knowledge Gap About Diversity in Clinical Trials

Finanznachrichten News

NORTHAMPTON, MA / ACCESSWIRE / August 17, 2023 / Walgreens Boots Alliance

Originally published by Walgreens Boots Alliance

By Sarah Cason, Walgreens Stories

Here's a statistic to stop you in your tracks: 75 percent of all participants in the FDA's 2020 clinical trials identified as white. Compare this to the fact that the highest prevalence rates of health disparities are observed in racial and ethnic minority groups.

Because of this, improving diversity in clinical trials can be-at its most literal-a matter of life and death. And it's a mission that Walgreens has put at the forefront of its U.S. Healthcare strategy.

To spread the word about the importance of representation in clinical trials, Walgreens focused part of its sponsorship at this year's Black Women's Expo on educating the community about how participation from people of all races can move us closer to achieving more equitable health outcomes. Additionally, diverse Walgreens suppliers, beauty consultants and pharmacists were on hand to celebrate and empower the health of Black women.

Alethia Jackson, SVP, ESG and chief DEI officer for the U.S. at Walgreens Boots Alliance, cut the ribbon to kick off the 28th year of the expo.

Joining Jackson at the expo was Kendal Whitlock, head of digital optimization, clinical trials at WBA.

Whitlock, who holds a master's degree in public health and has spent 20 years working in the pharmaceutical industry, wants people to understand that misgivings are understandable, but through clinical trial participation, you can be a catalyst for improving health in your community.

"There's a foundational lack of knowledge of what clinical trials are among the public. Candidly, people think they're guinea pigs," says Whitlock. "On top of that, there is a history of 350 years of transgressions against people's bodies-it's not just Henrietta Lacks and it's not just Tuskegee, but worldwide. So whether it's a lack of access to research professionals, the inconvenience of traveling to clinical sites, or maybe physician populations are short on time-but whatever the reason, it leaves people with gaps in understanding the process."

Whitlock joined Walgreens clinical trials team members Jim Carroll, head of real world evidence; Scott Chavers, senior director, epidemiology; Iyue Sung, director, clinical data sciences, and Mindy Bertram, director, patient recruitment and retention, as well as pharmacists and diverse suppliers in Walgreens booth at the expo to answer questions visitors had about clinical trials and explain how they could get involved.

Pharmacists at the expo provided more than 5,600 health services, including immunizations, blood pressure screenings, and health and medical consultations to attendees. Pharmacists Cornetta Levi and Latasha Guy helped to perform these services and took part in a mainstage presentation about achieving healthcare equity through local pharmacy access.

Whitlock joined Levi and Guy in the presentation to share critical data like the fact that only 5 percent of all people participate in clinical trials. In other words, the development of drugs and other therapies are based on a fraction of peoples' physical reactions and genetics, leaving physicians less equipped to speak to the effect they may have on Black people.

Whitlock hopes attendees left the conference feeling more educated and empowered to learn more about their health and how that can lead to improved research in clinical trials.

"We hope people came away educated and empowered so that they can have agency in their health journey," said Whitlock. "Patients need to understand the relevance because if they ask their provider if a medical product was developed with patients like them, and the provider can't give a definitive yes or no, then the patient is less adherent to that medication. And then the outcomes of whatever they're managing, say it's something like hypertension, are less controlled. So, not having that evidence is a lose-lose. It's not only a scientific imperative, but a moral imperative to diversify clinical trials so that the experience of managing illness is equitable."

Click here to learn more about clinical trials with Walgreens from Kendal Whitlock.

Walgreens Boots Alliance, Thursday, August 17, 2023, Press release picture

Kendal Whitlock, head of digital optimization, clinical trials at Walgreens Boots Alliance, speaks in Walgreens presentation, "Local Healthcare Reimagined," at the 2023 Black Women's Expo.

View additional multimedia and more ESG storytelling from Walgreens Boots Alliance on 3blmedia.com.

Contact Info:
Spokesperson: Walgreens Boots Alliance
Website: https://www.3blmedia.com/profiles/walgreens-boots-alliance
Email: info@3blmedia.com

SOURCE: Walgreens Boots Alliance

View source version on accesswire.com:
https://www.accesswire.com/774827/Bridging-the-Knowledge-Gap-About-Diversity-in-Clinical-Trials

© 2023 ACCESSWIRE
Treibt Nvidias KI-Boom den Uranpreis?
In einer Welt, in der künstliche Intelligenz zunehmend zum Treiber technologischer Fortschritte wird, rückt auch der Energiebedarf, der für den Betrieb und die Weiterentwicklung von KI-Systemen erforderlich ist, in den Fokus.

Nvidia, ein Vorreiter auf dem Gebiet der KI, steht im Zentrum dieser Entwicklung. Mit steigender Nachfrage nach leistungsfähigeren KI-Anwendungen steigt auch der Bedarf an Energie. Uran, als Schlüsselkomponente für die Energiegewinnung in Kernkraftwerken, könnte dadurch einen neuen Stellenwert erhalten.

Dieser kostenlose Report beleuchtet, wie der KI-Boom potenziell den Uranmarkt beeinflusst und stellt drei aussichtsreiche Unternehmen vor, die von diesen Entwicklungen profitieren könnten und echtes Rallyepotenzial besitzen

Handeln Sie Jetzt!

Fordern Sie jetzt den brandneuen Spezialreport an und profitieren Sie von der steigenden Nachfrage, der den Uranpreis auf neue Höchststände treiben könnte.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.